Status:
COMPLETED
Comparison of EPM-IX to Currently Used Specimen Transportation and Extraction Devices ( CGI-EPM-IX )
Lead Sponsor:
Convergent Genomics, Inc.
Conditions:
SARS-CoV-2
Eligibility:
All Genders
18+ years
Brief Summary
This is a research study to evaluate the clinical utility of the Enhanced Preservation Media with Integrated Extraction (EPM-IX)
Detailed Description
This is a minimal risk study where patients at UroPartners Urology Group will consent to SARS-CoV-2 nasopharyngeal swab testing using both, a standard of care test with standard Viral Transport Medium...
Eligibility Criteria
Inclusion
- Subject must be ≥18 years of age
- Subject is a current patient at UroPartners and is willing to be tested for Covid- 19 during a routine visit
- Subject must be able to understand and willingly provide informed consent
Exclusion
- Cannot provide informed consent
Key Trial Info
Start Date :
February 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 21 2022
Estimated Enrollment :
205 Patients enrolled
Trial Details
Trial ID
NCT05281692
Start Date
February 2 2022
End Date
March 21 2022
Last Update
October 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UroPartners Urology Group
Chicago, Illinois, United States, 60657